ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: SA-PO374

Sorting Nexin 9 Facilitates Podocin Endocytosis in the Injured Podocyte

Session Information

Category: Glomerular Diseases

  • 1202 Glomerular Diseases: Immunology and Inflammation


  • Sasaki, Yu, Juntendo University, Tokyo, Japan

The irreversibility of glomerulosclerotic changes depends on the degree of podocyte injury. We have previously demonstrated the endocytic translocation of podocin to the subcellular area in severely injured podocytes and found that this process is the primary disease trigger. We identified the protein sorting nexin 9 (SNX9) as a novel facilitator of podocin endocytosis in a yeast two-hybrid analysis. SNX9 is involved in clathrin-mediated endocytosis, actin rearrangement and vesicle transport regulation.


We conducted co-immunoprecipitation assays to confirm the interaction between podocin and SNX9 using lysates of FLAG-podocinand GFP-SNX9-overexpressing cells. To map the podocin binding site(s) in SNX9, we tested the abilities of various truncated GFP-SNX9 constructs to co-precipitate with FLAG-podocin. To further demonstrate that podocin can directly bind to SNX9, we performed GST pull-down assays with purified recombinant proteins. To detect SNX9 expression in kidney samples, we subjected normal and adriamycin (ADR)-injected mice to immunofluorescence staining. To evaluate SNX9 expression in vitro, we performed immunofluorescence staining on non-treated and ADR-treated cultured human podocytes. To assess SNX9 expression in human kidney glomeruli, we subjected human kidney biopsy specimens to immunofluorescence staining.


Our results revealed and confirmed that SNX9 interacts with podocin exclusively through the Bin–Amphiphysin–Rvs (BAR) domain of SNX9. Immunofluorescence staining revealed the expression of SNX9 in response to podocyte adriamycin-induced injury both in vitro and in vivo. Finally, an analysis of human glomerular disease biopsy samples demonstrated strong SNX9 expression and co-localization with podocin in samples representative of severe podocyte injury, such as IgA nephropathy with poor prognosis, membranous nephropathy and focal segmental glomerulosclerosis.


We identified SNX9 as a facilitator of podocin endocytosis in severe podocyte injury and demonstrated the expression of SNX9 in the podocytes of both nephropathy model mice and human patients with irreversible glomerular disease.


  • Government Support - Non-U.S.